ervogastat

Ervogastat (PF-06865571) is a first-in-class, orally administered small molecule inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2). It is being developed for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. DGAT2 inhibition reduces hepatic triglyceride synthesis and accumulation, which are key drivers in the pathogenesis of NASH. Ervogastat has advanced to Phase 2 clinical trials and has been studied both as monotherapy and in combination with clesacostat (an acetyl-CoA carboxylase inhibitor). The drug was designed to address metabolic stability and safety concerns seen with earlier DGAT2 inhibitors[1][2][3][4][5][8].

Other names

2186700-33-2ervogastat [INN]BSOIY5AKQWBSOIY-5AKQWBSOIY 5AKQW